作為廣譜的細(xì)胞毒性抗腫瘤藥物，順鉑具有顯著的臨床療效，但隨著劑量增加出現(xiàn)的心臟毒性反應(yīng)明顯增加了腫瘤患者心血管疾病的風(fēng)險(xiǎn)。目前順鉑產(chǎn)生心臟毒性的機(jī)制主要包括細(xì)胞毒作用、氧化應(yīng)激與炎癥、心肌細(xì)胞凋亡和相關(guān)信號(hào)通路。重視順鉑心臟毒性的機(jī)制，加強(qiáng)對(duì)化療患者心臟的監(jiān)護(hù)與管理，積極研發(fā)特效的心臟保護(hù)劑，以提高化療的質(zhì)量。主要對(duì)順鉑產(chǎn)生心臟毒性的臨床表現(xiàn)、病理特征、作用機(jī)制、藥物相互作用及臨床防護(hù)措施的研究進(jìn)展進(jìn)行綜述。

As a commonly used cytotoxic antitumor drug, cisplatin has a major clinical efficacy. However, dose-dependent cardiotoxicity significantly increased the risk of cardiovascular disease. The mechanism of cardiotoxicity induced by cisplatin mainly includes cytotoxic effect, oxidative stress and inflammation, myocardium cell apoptosis, and related signaling pathways. The mechanism of cardiotoxicity induced by cisplatin is valued, the monitoring and management of heart of chemotherapy patients is strengthened, and new protective drugs to improve quality of chemotherapy are developed. Research progress on clinical manifestation, pathological characteristics, mechanism, drug interactions, and clinical preventive measures were summarized in this paper.

天津市衛(wèi)生計(jì)生委科技基金資助項(xiàng)目（2015KG110）